ArdorComm Media Group

Thursday, March 12, 2026 12:21 AM

Fortis Healthcare

IHH Healthcare Targets 7,000-Bed Capacity in India by 2028

IHH Healthcare has reiterated that it is on course to expand its hospital capacity in India to nearly 7,000 beds by 2028, marking an increase of over one-third from its current scale. The update comes after the successful completion of its open offer to acquire an additional stake in Fortis Healthcare. Following the open offer, IHH’s ownership now stands at 31.17% in Fortis Healthcare and 62.73% in Malar Hospitals. The company said the milestone positions it strongly for the next phase of growth in the Indian market. IHH Healthcare Group CEO Prem Kumar Nair said the conclusion of the Fortis open offer is a key step in advancing the group’s India strategy, aligning with its broader transformation efforts aimed at strengthening long-term resilience. He added that the company is well placed to drive innovation, enhance patient outcomes, and create sustainable value amid India’s rapidly evolving healthcare sector. Nair also highlighted that closer collaboration between Fortis Healthcare and Gleneagles Healthcare India will help unlock operational efficiencies and further improve the quality of care delivered nationwide. Echoing this outlook, Ashok Pandit, Group Chief Corporate Officer at IHH Healthcare, said the company is steadily expanding its footprint and remains committed to adding nearly 2,000 beds by 2028. Currently, IHH operates 35 hospitals with over 5,000 beds across 11 states in India, leveraging both operational and financial synergies to support its growth ambitions. Globally, IHH Healthcare has operations in 10 countries, including Malaysia, Singapore, Turkiye, India, and Greater China. Source: PTI

IHH Healthcare Targets 7,000-Bed Capacity in India by 2028 Read More »

Budget 2024: Pharma Industry Urges More Tax Breaks for R&D, Innovation, and Increased Healthcare Spending

Amidst the anticipation surrounding the upcoming Union Budget on February 1, the healthcare and pharmaceutical industry has outlined a comprehensive wishlist for Budget 2024, aiming for policies that foster innovation, research and development (R&D), and increased healthcare spending. Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, emphasized the need for conducive policies that offer direct and indirect tax benefits to pharmaceutical companies. The focus should be on critical areas such as innovation, R&D, and upgrading healthcare infrastructure. Jain highlighted the significance of continuous investments, especially in a sector with high risks and long gestation periods. Dr. Ashutosh Raghuvanshi, MD and CEO of Fortis Healthcare & President of NATHEALTH, called for a significant hike in healthcare spending to 2.5% of GDP. The proposals presented by NATHEALTH emphasize transformative changes to bridge regional healthcare disparities and strengthen the healthcare value chain. The aim is to enhance medical value travel, address MAT credit issues, and build local capabilities for healthcare services. Ameera Shah, Promoter and Managing Director of Metropolis Healthcare, underscored the importance of the upcoming budget in strengthening India’s healthcare ecosystem. Shah advocated for investments in critical areas like innovation, research, development, technology, and upgrading healthcare infrastructure. Additionally, she called for a 0% GST on diagnostic services, GST refunds on inputs, and rationalizing import tariffs on healthcare products to enhance accessibility and affordability. These recommendations collectively aim to position India as a reliable supplier of medicines and a custodian of global healthcare. The healthcare sector looks forward to policy stability, continuity, and transformative measures in the upcoming budget, recognizing the role it plays in combating present and future healthcare challenges. Source: CNBC-TV18

Budget 2024: Pharma Industry Urges More Tax Breaks for R&D, Innovation, and Increased Healthcare Spending Read More »